54 results about "Antibody activity" patented technology

This invention discloses a camel-derived CRP single-domain antibody, its preparation method, and its applications, relating to the biomedical field. The method involves enriching CRP antigen in alpaca leukocytes immunized with the antigen, followed by single-cell screening and sequencing. Through sequencing structural analysis, a recombinant plasmid of the camel-derived CRP antibody is constructed. This plasmid is cloned and transformed into eukaryotic cells to express related antibodies. Monoclonal antibodies with human CRP resistance are screened for expression. The VHH domain of the monoclonal antibody is cloned and expressed, and paired screening yields CRP-VHH monoclonal antibodies with antibody activity. This antibody can be used in ELISA kits, chemiluminescence kits, and latex kits, possessing the same functionality as existing kits. Furthermore, this antibody also has applications in the preparation of antitumor drugs.

The invention provides an anti-CD28 humanized single-domain antibody and a preparation method of the anti-CD28 humanized single-domain antibody. Specifically, the invention discloses a plurality of single-domain antibodies targeting CD28, humanized antibodies thereof, derived proteins, gene sequences for encoding the single-domain antibodies and the humanized antibodies, and expression vectors and expression systems for producing the single-domain antibodies and the humanized antibodies. The single-domain antibody provided by the invention is a CD28 non-agonistic antibody, can block the binding of CD28 and CD80, and can specifically bind to CD28 of human and monkeys. The single-domain antibody provided by the invention has high safety, and provides a research and development basis for development of antibody coupling drugs and multispecific antibody drugs. A bispecific antibody composed of the CD28 single-domain antibody and the targeting tumor antigen antibody can significantly enhance the activity of the CD3 bispecific antibody. The activity of a multi-specific antibody composed of the CD28 single-domain antibody, the targeting tumor antigen antibody and the CD3 antibody is significantly superior to that of the CD3 bispecific antibody.

This disclosure provides anti-VEGF antibodies formulated as high-concentration aqueous pharmaceutical compositions suitable for injection, preferably intravitreal injection. Aqueous pharmaceutical compositions are useful for delivering a high concentration of the antibody active ingredient to a patient without high levels of antibody aggregation and without a high level of sub-visible particulate matter. An aqueous composition of the disclosure comprises an antibody having a concentration of at least 50 mg / mL. An aqueous pharmaceutical composition of the disclosure includes a sugar, a buffering agent, and a surfactant.

Compositions and methods for modulating antibody activity are disclosed.

The application discloses a CRP camel-derived single-domain antibody and a preparation method and application thereof, relates to the field of biological medicines, and is characterized in that: white blood cells of a llama immunized with a CRP antigen are enriched, and then single-cell screening and sequencing are performed. Through sequencing structure analysis, a camel-derived CRP antibody recombinant plasmid is constructed, a related antibody is expressed in a eukaryotic cell through cloning transformation, a single antibody with human CRP resistance is screened, a VHH domain of the single antibody is cloned and expressed, and a single antibody with CRP-VHH antibody activity is obtained through pairing screening. The antibody can be applied to an ELISA kit, a chemiluminescence kit and a latex kit, has the same functions as existing kits, and still has the use in the preparation of an anti-tumor drug.

The invention relates to a glycosylated hemoglobin HbA1c freeze-drying detection reagent and a preparation method and application thereof.The preparation method comprises the steps that surface aminated polystyrene microspheres are prepared through an emulsion polymerization method, then double bonds are introduced through Schiff base reaction and methylacrolein reaction, and the glycosylated hemoglobin HbA1c freeze-drying detection reagent is obtained. Then preparing anionic polystyrene microspheres with hydrophilic chains through free radical polymerization, and preparing freeze-dried powder of the HbA1c detection reagent R1 by adopting the anionic polystyrene microspheres; the preparation method comprises the following steps: preparing a hydrophilic cross-linking agent 2, 5-bis (2, 4-dihydroxy-6-formylphenoxy) terephthalaldehyde, then carrying out a Schiff base reaction on the hydrophilic cross-linking agent 2, 5-bis (2, 4-dihydroxy-6-formylphenoxy) terephthalaldehyde and HbA1c mAb to prepare an HbA1c oligomer, and preparing the HbA1c detection reagent R2 freeze-dried powder by using the HbA1c oligomer. The glycosylated hemoglobin HbA1c freeze-drying detection reagent prepared by the invention has the advantages of high antigen binding efficiency, excellent detection sensitivity, sufficient retention of antibody activity and strong detection specificity.

The invention provides a CD47 antibody specifically activated by a tumor microenvironment. Specifically, the invention provides a bispecific antibody which is connected with a substrate and a masking body which are highly expressed in a tumor environment and can recognize cleavage in a chemical coupling manner. The antibody activity of the bispecific antibody is hindered in normal tissue, and the antibody activity is activated in a tumor environment. In addition, the bispecific antibody also has significantly reduced toxic and side effects.

The present invention discloses a manufacturing method of a self-driven microfluidic chip and the self-driven microfluidic chip. The manufacturing method includes steps of antibody encapsulation and antibody immobilization; wherein, antibody encapsulation includes a fluorescent dye encapsulation method or a fluorescent microsphere encapsulation method; antibody immobilization includes an EPI immobilization method or a latex microsphere immobilization method, and both encapsulation and immobilization are quantitatively carried out with the aid of an instrument. The self-driven microfluidic chip encapsulates and immobilizes antibodies by the foregoing method. The beneficial effects of the present invention are that the antibodies encapsulated and immobilized by the manufacturing method have a long active time. After the labeled reaction occurs for the encapsulated fluorescent antibodies, they can break free from the restraint and flow with the sample; the antibodies immobilized in the detection area remain in place after the immune reaction to retain the double antibody sandwich label on the micro-columns in the detection area of the chip. When the self-driven microfluidic chip is used for routine examination of heart diseases, the detection result can be obtained by detecting the fluorescence labeling signal intensity of the double antibody sandwich retained in the detection area with a fluorescence detector.

The invention belongs to the technical field of molecular biology, and particularly relates to an anti-GLP-1R nano antibody as well as a preparation method and application thereof. The invention provides an anti-GLP-1R nano antibody, and also provides a construction method of the anti-GLP-1R nano antibody. The method comprises the following steps: constructing GLP-1R overexpression plasmids and overexpression cell strains, immunizing alpaca by using the plasmids and the cells to obtain PBMC cells, extracting total RNA, carrying out reverse transcription to obtain cDNA, amplifying antibody gene segments through PCR, connecting the segments to phage expression vectors, and electrically transforming the constructed vectors into SS320 competent cells to finally obtain the GLP-1R immune antibody library. The method comprises the following steps: carrying out cell panning for one round, carrying out Cell ELISA detection to obtain an antibody combined with GLP-1R, carrying out sequencing to obtain an antibody sequence, obtaining antibody protein through mammalian cells, and carrying out FACS detection by using CHOK1-GLP-1R cells to finally obtain the antibody combined with GLP-1R. The method is simple and convenient to operate, and the activity of the antibody obtained by using a mammalian cell expression system is closer to that of a natural antibody.

The invention relates to the technical field of antibody titer digitization analysis, in particular to a brucellosis antibody titer digitization analysis system based on a spectrophotometric method.According to the brucellosis antibody titer digitization analysis system, a full-time reaction kinetics absorbance curve is obtained through a data acquisition module; a signal decomposition module is utilized to decouple the signal into a low-frequency trend component and a high-frequency detail component; further identifying a reaction kinetics phase state through a low-frequency trend analysis module to lock an effective reaction interval and generate first-dimension analysis data, and controlling a high-frequency detail analysis module to generate second-dimension analysis data by taking the first-dimension analysis data as a time domain gating basis; finally, the comprehensive evaluation module constructs a coupling weight model based on the reaction kinetics phase state, and fuses the two-dimensional data to generate a comprehensive antibody activity evaluation value; according to the process, a self-adaptive analysis mechanism conforming to a reaction evolution rule is constructed, and accurate determination of the titer of the antibody is realized.

The invention relates to an antigen binding protein, an antibody or an antibody active fragment obtained by immunizing a camelidae animal with a Sumo tag protein. The antibody capable of realizing specific recognition and combining with the Sumo tag protein is screened, identified and prepared by virtue of an immune system of a camelidae animal, and the obtained antibody is high in specificity, can be used for target antigen detection and has potential clinical diagnosis and treatment values; the antibody provided by the invention is simple in structure, easy to carry out genetic engineering modification, easy to realize humanization, high in stability, low in mass production cost and beneficial to realizing large-scale production.

This invention provides a method for producing PD-1 antibodies with high protein expression levels, high antibody activity, and / or high galactosyl levels. This method involves culturing cells in a culture medium until the target protein is obtained. The culture temperature is 37°C, which is then lowered to 33-34°C on the 5th day of culture. The culture medium also contains additives, namely galactose and manganese chloride. The concentrations of galactose and manganese chloride added are 0.05-6 mM and 0.05-3 μM, respectively. The culture medium consists of a basal medium and a feed medium. The basal medium is Star CHO, and the feed medium is Star CHO Feed and CDFS36. The basal medium also contains 1 g / L poloxamer. The Star CHO Feed feed is added at 4% / 5% / 6% / 6% / 5% / 4% of the initial culture volume each time, and the CDFS36 feed is added at 0.4% / 0.5% / 0.6% / 0.6% / 0.5% / 0.4% of the initial culture volume each time. The additives galactose and manganese chloride, as well as the Star CHO feed feed... Feed and CDFS36 were added every 2 days starting from day 3 of culture; the dissolved oxygen in the culture system was 40%, and the pH was 7.0 ± 0.1; the rotation speed of the culture system was 240 rpm.

The present invention discloses a fluorescent antibody sealing solution, a preparation method and uses thereof. The fluorescent antibody sealing solution is mainly composed of 5% - 20% trehalose, 0.1% - 1.0% BSA, 0.1% - 1.0% polyvinylpyrrolidone, 0.1% - 5.0% sorbitol, and the rest is HEPES buffer solution by mass percentage. This sealing solution is suitable for sealing fluorescent microsphere antibodies; when used for sealing fluorescent dye antibodies, it also includes 0.05% - 0.1% sodium hyaluronate. The preparation method includes first preparing 20 mmol / L HEPES buffer solution, adjusting the pH to 7.4 - 7.6 with 1 mol / L sodium hydroxide, and then successively adding the substances in the sealing solution formula and dissolving them fully. The beneficial effects of the present invention are that the sealing solution has a simple formula and is convenient to prepare. After the fluorescent antibody sealed by it undergoes a labeling reaction, it can break free from the bondage and flow with the sample, and can maintain the antibody activity for a long time.

The invention provides an anti-tetanus antibody as well as preparation and application thereof, and relates to the field of antibodies. The amino acid sequence of the tetanus-resistant antibody heavy chain CDR is as shown in SEQ ID NO: 1-3; the amino acid sequence of the light chain CDR of the antibody is as shown in SEQ ID NO: 4-6. The antibody disclosed by the invention is high in activity and affinity, and has the application prospect of preparing a medicine for preventing and / or treating tetanus or a product for detecting the tetanus toxin level with a non-diagnostic purpose and the like.

The invention discloses a retinol binding protein detection kit and a preparation method thereof. The detection kit comprises a reagent R1 and a reagent R2. The reagent R1 comprises an oxidizing agent and is beneficial to maintaining the structural stability of the retinol binding protein. And the R2 reagent comprises latex microspheres loaded with a retinol binding protein antibody. According to the present invention, the antibody directional coupling technology is adopted, such that the stable thioether bond is formed between the retinol binding protein antibody and the latex microsphere, the retinol binding protein antibody is coupled to the latex microsphere, the antibody is connected with the microsphere through the Fc region, and the Fab region extends outward so as not to affect the antibody active region configuration, and the efficient combination with the sample antigen is achieved;

The invention relates to a humanized antibody of a dermatomyositis specific antigen as well as a preparation method and application of the humanized antibody. Amino acid sequences of HCDR1, HCDR2 and HCDR3 of a heavy chain of the antibody respectively comprise sequences as shown in SEQ ID No.6 to SEQ ID No.8, and amino acid sequences of LCDR1, LCDR2 and LCDR3 of a light chain of the antibody respectively comprise a sequence as shown in SEQ ID No.9, a sequence as shown in GQD and a sequence as shown in SEQ ID No.10. The anti-MDA5 human monoclonal antibody obtained through screening is high in activity, good in stability and high in MDA5 binding specificity, can serve as a reference standard for qualitative detection of MDA5 positive, can also be used for quantitative detection of the anti-MDA5 autoantibody level in patients suffering from inflammatory myopathy or complications of the inflammatory myopathy, and can be used for clinical application. And a new tool is provided for diagnosis, monitoring, treatment and the like of dermatomyositis and complications thereof.

This invention discloses a Pt-Ni@erGO electrochemical probe, its preparation method, and its applications. The Pt-Ni@erGO electrochemical probe comprises an erGO matrix and Pt-Ni nanoparticles supported on the erGO matrix. The Pt-Ni@erGO electrochemical probe of this invention uses erGO as a matrix to grow Pt-Ni alloy nanoparticles in situ. erGO simultaneously exhibits two functions to enhance electrochemical detection sensitivity: firstly, it acts as a carrier to load high-density Pt-Ni alloy nanoparticles, reducing the shielding effect of biorecognition elements on the catalytic sites of nanozymes; secondly, it acts as a biorecognition element to specifically bind to *E. coli*. Through the rational combination of erGO and Pt-Ni nanoparticles, the obtained Pt-Ni@erGO possesses high antibody-like activity and electrocatalytic activity.

The present invention relates to a method for detecting cell activity of an anti-sclerostin (SOST) antibody or sclerostin, the method comprising: co-culturing a cell line capable of stably expressing Wnt1 protein and a cell line capable of expressing Luciferase protein under the regulation of TCF / LEF elements to detect the activity of the anti-SOST antibody or SOST. The molecular mechanism of action (MOA) of the present invention is clear, high in specificity, high in sensitivity, and good in robustness, and is of great significance for anti-SOST antibody drug screening, quality control, and clinical application.

The present application relates to the technical field of in vitro diagnosis protein marker, in particular to a preservative for horseradish peroxidase marker and application thereof. The present application provides a preservative for horseradish peroxidase marker and application thereof. The preservative comprises lecithin 0.05-1.0 g / L, bovine serum albumin 2-10 g / L, sodium chloride 5-30 g / L, polyaspartic acid 2-10 g / L, and the rest is glycerol. The preservative can significantly improve the storage stability of enzyme-labeled product, and the activity of enzyme-labeled antibody can still maintain more than 70% after 21 days of storage at 37 DEG C. In the bottle opening stability test, the activity of enzyme-labeled antibody can maintain more than 87% after 45 days of storage at 4 DEG C.

The invention discloses a monkey pox virus B6-A29 and A35-M1 fusion antigen and application thereof, and belongs to the technical field of biological medicine. The B6-A29 and A35-M1 fusion protein with good stability and uniform quality is designed, the neutralizing antibody activity is remarkably enhanced, the in-vivo protection effect is good, and the long-term protection effect is achieved. Compared with simple superposition of a single protein mixing effect, the method has better humoral immunity and cellular immunity, and the production, purification and quality control processes are simpler, more stable and lower in cost compared with a scheme of respectively producing four independent proteins and then mixing, and more accord with the requirements of vaccine industrial production.

The invention discloses a conjugate of phosphorylated Tau protein and magnetic beads as well as a preparation method and a kit of the conjugate, and relates to the technical field of immunoassay. The modified magnetic beads modified with azide groups and the modified anti-phosphorylated Tau protein antibody modified with DBCO groups are efficiently and directionally coupled in a click chemistry mode, and compared with a traditional physical adsorption or non-specific chemical coupling method, the method has the advantages of being high in coupling efficiency, high in binding stability, high in antibody activity retention rate and the like; compared with the prior art, the magnetic bead provided by the invention has the advantages that the capture efficiency and specificity of the magnetic bead on low-abundance p-Tau in blood can be obviously improved, the lower detection limit is as low as 0.3 pg / mL or below, excellent accuracy is shown in early AD diagnosis, subtle changes of p-Tau in the blood of an early AD patient can be accurately identified, and a reliable tool is provided for early screening, disease course monitoring and intervention effect evaluation of AD.

The invention relates to the field of fluorescent probes, in particular to a compound, a fluorescent cluster, an immunofluorescent cluster and a preparation method and application of the compound, the compound is shown in the formula (I), the compound has complete water solubility and has the high signal-to-noise ratio of fluorescence imaging, the fluorescent cluster prepared from the compound also has complete water solubility, active functional groups are clear and controllable, and the immunofluorescent cluster has the high fluorescence imaging signal-to-noise ratio and the high fluorescence imaging signal-to-noise ratio. The fluorescent cluster is high in fluorescence brightness and high in photobleaching resistance, the fluorescent cluster can be coupled with a nano antibody under the condition of pure water to obtain an immunofluorescent cluster, the antibody activity is not affected, and the fluorescent cluster can be used for a cell immunofluorescent staining probe. # imgabs0 #

Provided is a tumor microenvironment specifically activated CD47 antibody. Specifically, provided is a bispecific antibody which is, in a chemical coupling manner, linked to a substrate and a blocker which are highly expressed in a tumor environment and can recognize cleaving. The antibody activity of the bispecific antibody in a normal tissue is suppressed, and the antibody activity of the bispecific antibody is activated in a tumor environment. In addition, the bispecific antibody also has a significantly reduced toxic and side effect.

The application relates to an antigen binding protein, an antibody or an antibody active fragment obtained by immunizing a camelid with a Sumo tag protein. The application relies on the immune system of the camelid to screen, identify and prepare an antibody specifically recognizing and binding the Sumo tag protein. The obtained antibody has high specificity and can be used for target antigen detection, and has potential clinical diagnosis and treatment values. The antibody provided by the application has simple structure, is easy to be genetically engineered, is easy to be humanized, has high stability, has low mass production cost, and is beneficial to realize large-scale production.

The invention discloses a core-shell structure microneedle of a programmed co-delivery oxygen vacancy engineered self-oxygen-supply nano platform and an ICB antibody and a preparation method of the core-shell structure microneedle, a needle tip of the core-shell structure microneedle comprises a shell layer and a core layer located in the shell layer, and the shell layer is a PVA shell layer capable of being rapidly dissolved; mXene (at) RuO2 nanosheets grafted with GOx and HbO2 are dispersed in a PVA solution and then poured in a PDMS mold to be dried, and the composite material is prepared. The core layer is a core layer with ROS responsiveness, SiO2 nanoparticles loaded with aPD-1 are dispersed in a PVA solution, and the SiO2 nanoparticles loaded with aPD-1 and a TSPBA solution are jointly poured in a PVA shell layer capable of being rapidly dissolved. The core-shell structure microneedle can programmatically release an enzymatic cascade reaction nano-platform ROS generator MRuGH and an ICB antibody, the antibody activity is protected, programmed immunotherapy of malignant tumors is controlled in a time-space mode, and ICB treatment sensitivity is remarkably improved.

The application discloses a feline panleukopenia virus, feline herpes virus and feline calicivirus yolk antibody preparation and a preparation method and application thereof. The feline triple yolk antibody preparation comprises a core material, and the core material comprises feline calicivirus yolk antibody, feline panleukopenia virus yolk antibody, feline herpes virus type 1 yolk antibody and probiotics. The application can produce specific neutralization to feline calicivirus, feline panleukopenia virus and feline herpes virus type 1, significantly reduces the infection rate and the severity of clinical symptoms, is stably released in the gastrointestinal tract after oral administration, the antibody activity retention rate is more than 90%, the probiotics synergistically regulate intestinal microecology, enhance the immune response of the body and improve the overall protection efficiency.

The present invention relates to a new cell-based assay for determining antigen expression in primary tumor samples. The method further relates to the determination of antigen and protease expression in primary tumor samples. The method allows robust determination of antigen and / or protease expression without the need to digest the tumor samples. The method further allows for selection of antibodies and for selection of protease-cleavable linkers for the treatment of tumors.

The present invention belongs to the field of biomedicine, and in particular to a humanized anti-human CD132 monoclonal antibody and its application. Based on the monoclonal chimeras 2D4 and 5H10 previously obtained in this laboratory, the present invention screened and obtained high-affinity monoclonal humanized antibodies h2D4H4K12 and / or h5H10H6K4 that can target human CD132 by humanizing the target antibody. On the basis of not weakening the antibody activity, the immunogenicity of the maternal chimera was reduced, and the risk that the patient using the drug may produce an immune response to the antibody was further reduced. It has good application prospects in the treatment of autoimmune diseases (such as rheumatoid arthritis, systemic lupus erythematosus, etc.) associated with IL-4, IL-7, IL-9, IL-15 and / or IL-21 cytokines.